Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial
Acta Haematologica · 02.03.2026 · 1-14
DOI: 10.1159/000551325 ↗Kurz gefasst
Fachartikel in der Zeitschrift Acta Haematologica, online erschienen am 02.03.2026. Verfasst von Ilana Levy Yurkovski und 10 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Institute, Bnai Zion Medical Center, Haifa, Israel, silana90@technion.ac.il. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Lymphoma has recovery rates above 60%, but many survivors experience impaired quality-of-life (QoL) requiring survivorship care. This study evaluated the role of an integrative oncology (IO) clinic in managing lymphoma survivors.
Methods
In this exploratory preference-based controlled trial, adults in remission after lymphoma treatment were allocated to two groups: those attending the IO survivorship clinic (intervention) and those declining (control). The intervention included complementary medicine, spiritual, and social support, delivered weekly for up to 6 months in addition to standard follow-up. The primary outcome was QoL improvement (EQ-5D-5L index). Secondary outcomes included symptom relief (MYCAW), cognitive function, and perceived control.
Results
Twenty-nine patients were enrolled: 15 in the intervention and 14 in the control group. Over the first 3 months, a significant time × group interaction in EQ-5D-5L scores favored the intervention (p = 0.005), reflecting superior QoL trajectory. MYCAW concerns also improved significantly in the intervention group across 6 months (p = 0.005 and p = 0.03). At 3 months, FACT Cog-Oth scores were significantly higher in the intervention arm (p = 0.01), indicating better “other” cognitive functions (e.g., memory, clarity, confusion). To note, adherence to IO mainly decreased after 3 months.
Conclusion
In this exploratory preference-based study, an IO survivorship clinic for lymphoma survivors was associated with improvements in QoL, especially for adherent patients. Given the preference-based design, these findings should be interpreted cautiously and viewed as hypothesis-generating rather than confirmatory. Further studies are warranted to evaluate long-term benefits and sustainability of this approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Hematology Institute, Bnai Zion Medical Center, Haifa, Israel, silana90@technion.ac.il.
- Integrative Medicine Service, Bnai Zion Medical Center, Haifa, Israel, silana90@technion.ac.il.
- Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel, silana90@technion.ac.il.
- Integrative Medicine Service, Bnai Zion Medical Center, Haifa, Israel.
- Rappaport Faculty of Medicine, Technion - Israel Institute of Technology, Haifa, Israel.
- Internal Medicine B Department, Bnai Zion Medical Center, Haifa, Israel.
Zitieren
APA
Levy Yurkovski, I., Attias, S., Schiff, E., Cohen-Naznin, O., Anahory, E., Gross-Geva, Y., Oved, A., Bleiweiss, N., Caspi-Biran, S., Awad, S., & Tadmor, T. (2026). Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial. Acta Haematologica, 1-14. https://doi.org/10.1159/000551325
Vancouver
Levy Yurkovski I, Attias S, Schiff E, Cohen-Naznin O, Anahory E, Gross-Geva Y, et al. Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial. Acta Haematologica. 2026:1-14. doi:10.1159/000551325
BibTeX
@article{LevyYurkovski2026,
author = {Levy Yurkovski, Ilana and Attias, Samuel and Schiff, Elad and Cohen-Naznin, Ohad and Anahory, Esther and Gross-Geva, Yael and Oved, Anat and Bleiweiss, Niki and Caspi-Biran, Sharon and Awad, Sally and Tadmor, Tamar},
title = {Effectiveness of Integrative Medicine in the Management of Lymphoma Survivors: An Exploratory Preference-Based Controlled Trial},
journal = {Acta Haematologica},
year = {2026},
pages = {1--14},
doi = {10.1159/000551325}
}
EUVIMED